Advertisement

Topics

Search Results for "Gram Negative Bacteraemia Duration Antibiotics"

22:23 EDT 22nd October 2017 | BioPortfolio

Original Source: Antibiotic Durations for Gram-negative Bacteremia

Gram-negative bacteremia (GNB) is a frequent hospital & community-acquired infection, yet there is as yet no evidence from randomized studies on the optimal duration of antibiotic therapy. This point-of-care, multicenter randomized controlled non-inferiority trial will randomize 500 patients with GNB on day 5 of appropriate antibiotic therapy to either (1) a total of 7 days of antibiotic therapy, (2) a total of 14 days of antibiotic therapy, or (3) an individualized duration of...

Matching Channels

Vancomycin

Vancomycin is an antobiotic indicated for the treatment of serious, life-threatening infections by Gram-positive bacteria that are unresponsive to other less-toxic antibiotics. In particular, vancom...

Gram stain

Antibiotics

Prophylactic antibiotics

Selection and Use of Antibiotics

Matching News

Mutabilis joins European ENABLE project to develop new antibiotics

Mutabilis has been selected by the European Gram-negative antibacterial engine (ENABLE) project to focus on the improved development of antibiotics against infections caused by multi-resistant, Gram-n...

How long should I take antibiotics? Exploring the Goldilocks problem.

Antibiotics save lives, but antibiotics can have negative effects.  When patients have bacterial infections, we want to treat them to prevent complications of the bacterial infection, but not treat t...

Membrane Vacuum Cleaner Suggested as Potential Gram-negative Bacteria Target

Scientists at the U.K.’s University of Newcastle suggest that a bacterial membrane protein that acts as a type of membrane vacuum cleaner could represent a promising new target for rendering harmful...

Healthcare-associated Gram-negative market to be worth $3.6 billion by 2026; report

The global marketplace for healthcare-associated infections (HAIs) caused by Gram-negative bacteria across…

GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Gram-Positive and Gram-Negative Panels

Thursday, June 29th 2017 at 8:30pm UTC CARLSBAD, Calif.–(BUSINESS WIRE)– GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing sy...

Polyphor Achieves Ahead Of Schedule First Milestone From Wellcome Trust For The Development Of Novel Antibiotics Against Gram-Negative Multidrug - Resistant Pathogens

  Life Sciences Jobs   ...

EligoChem Awarded up to $4.8M from CARB-X to Select and Develop Antimicrobial Peptides as Gram-Negative Antibiotics

EligoChem Ltd, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, has announced that it has been awarded up to $4.8 million non-dilutive funding fro...

FDA Approves Delafloxacin (Baxdela) for Skin Infections

The new antibiotic works against both gram-positive and gram-negative bacteria, including MRSA. FDA Approvals

Matching PubMed Articles

PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia.

Antibiotic overuse drives antibiotic resistance. The optimal duration of antibiotic therapy for Gram-negative bacteraemia (GNB), a common community and hospital-associated infection, remains unknown a...

A tobramycin vector enhances synergy and efficacy of efflux pump inhibitors against multidrug-resistant Gram-negative bacteria.

Drug efflux mechanisms interact synergistically with the outer membrane permeability barrier of Gram-negative bacteria leading to intrinsic resistance that presents a major challenge for antibiotic dr...

Membrane-active macromolecules kill antibiotic-tolerant bacteria and potentiate antibiotics towards Gram-negative bacteria.

Chronic bacterial biofilms place a massive burden on healthcare due to the presence of antibiotic-tolerant dormant bacteria. Some of the conventional antibiotics such as erythromycin, vancomycin, line...

Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance.

The increasing use of polymyxins(1) in addition to the dissemination of plasmid-borne colistin resistance threatens to cause a serious breach in our last line of defence against multidrug-resistant Gr...

Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative 'superbugs'.

The emergence of antimicrobial resistance of Gram-negative pathogens has become a worldwide crisis. The status quo for combating resistance is to employ synergistic combinations of antibiotics. Faced ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement